The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 15, 1986

Filed:

Nov. 12, 1981
Applicant:
Inventors:

Sheung T Kam, Vernon Hills, IL (US);

William L Matier, Libertyville, IL (US);

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07C / ; C07C / ; C07D / ; C07D / ;
U.S. Cl.
CPC ...
514487 ; 560110 ; 560 24 ; 560 10 ; 560 20 ; 560 49 ; 560 56 ; 560 67 ; 560 74 ; 560100 ; 560146 ; 560196 ; 560160 ; 549 65 ; 549 66 ; 549 68 ; 549 69 ; 548337 ; 548225 ; 548233 ; 548469 ; 548538 ; 548542 ; 546245 ; 546248 ; 544383 ; 544390 ; 544160 ; 544176 ; 544 581 ; 544 584 ; 514522 ; 514533 ; 514535 ; 514540 ; 514534 ; 514478 ; 514481 ; 514482 ; 564 48 ; 564 59 ; 564 90 ; 564 94 ; 514486 ; 558416 ;
Abstract

Novel compounds of the general formula ##STR1## wherein Ar represents a substituted or unsubstituted aromatic or heterocyclic group; W represents alkylene of from 1 to about 10 carbon atoms; and B represents --NR.sub.2 COR.sub.1, --NR.sub.2 CONR.sub.1 R.sub.3, --NR.sub.2 SO.sub.2 R.sub.1, --NR.sub.2 SO.sub.2 NR.sub.1 R.sub.3, or --NR.sub.2 COOR.sub.1 wherein R.sub.1, R.sub.2 and R.sub.3 may be the same or different and may be hydrogen, alkyl, alkoxyalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R.sub.1 is not hydrogen when B is --NR.sub.2 SO.sub.2 R.sub.1 or --NR.sub.2 COOR.sub.1, or R.sub.1 and R.sub.3 may together with N form a 5 to 7 momoered heterocyclic group; and the pharmaceutically acceptable salts thereof. These compounds exhibit .beta.-adrenergic blocking activity and are also useful in the treatment of glaucoma.


Find Patent Forward Citations

Loading…